- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06327087
Appetite and Dietary Intake Across the Menstrual Cycle
April 27, 2026 updated by: Sarah Purcell, University of British Columbia
Appetite and Energy Balance Parameters Across the Menstrual Cycle
Lay language summary: Women are younger and menstruating about monthly ("pre-menopausal") often have fluctuations in the food they eat ("dietary intake") across the menstrual cycle.
However, relationships between food intake and appetite, metabolism, body composition (i.e., the proportion of muscle and fat), physical activity and premenstrual symptoms have not been reported.
This study will measure appetite and food intake in laboratory and usual life settings in healthy pre-menopausal women in two hormonally different parts of the menstrual cycle.
Data on ovarian hormones, metabolism, body composition, physical activity and premenstrual symptoms will also be collected to assess their potential relationship with food intake.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Energy balance parameters (dietary intake and energy expenditure) are influenced by gonadal hormones, such as estradiol and progesterone that fluctuate across the menstrual cycle in pre-menopausal women.
Dietary intake varies across the menstrual cycle, with higher self-reported energy intake in the luteal phase.
However, it is unclear how physiological and behavioral parameters such as appetite, resting metabolic rate, body composition, physical activity, or premenstrual symptoms relate to energy intake fluctuations.
Furthermore, only two studies have measured free-living objective dietary intake across the menstrual cycle, neither of which have measured other aspects of energy balance in detail.
This study will help address these knowledge gaps by characterizing several aspects of energy balance in both laboratory and free-living settings in healthy pre-menstrual women across the menstrual cycle.
Twenty-three women (for complete data on n=18) aged 18-35 without major comorbidities and with normal menstrual cycles will be enrolled in an observational trial.
In addition to a baseline visit to measure body composition, participants will undergo two 4.5-hour study visits, one of which will occur in the follicular phase and the other in the luteal phase (as confirmed with multiple low-burden methods including self-reported menstrual cycle history and urinary luteinizing hormone).
Participants will be given a two-day run-in diet prior to each study day to ensure energy balance.
On each study day visit, participants will undergo a resting metabolic rate test followed by a series of fasting saliva samples quantitatively pooled to measure estradiol and progesterone.
Following collection of fasted ratings of appetite, participants will be provided with a standard breakfast meal.
Appetite ratings will be repeated 30, 60, 90, 120, 150, and 180 minutes after the meal.
Questionnaires related to eating behavior will also be completed during this time.
After the 180-minute timepoint, participants will be provided with a buffet-like lunch meal with instructions to eat as much or as little as they would like; this will allow measurement of ad libitum dietary intake at a single meal.
To assess free-living ad libitum dietary intake, participants will receive three days of food boxes tailored to their preferences, with uneaten food returned at the end of the three-day period.
After each study visit, participants will be asked to record their dietary intake and appetite (three days) and wear and activity monitor (seven days).
Differences in outcomes between visits will be assessed using paired samples t-tests and relationships among variables will be assessed via Pearson correlations.
This study will provide preliminary evidence of the factors associated with dietary intake fluctuations across the menstrual cycle and provide essential preliminary data that could inform future weight management and health-promotion strategies.
Study Type
Observational
Enrollment (Actual)
31
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
British Columbia
-
Kelowna, British Columbia, Canada, V1V1V7
- University of British Columbia - Okanagan
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
N/A
Sampling Method
Non-Probability Sample
Study Population
Healthy sedentary or recreationally active females with normal menstrual cycles
Description
Inclusion Criteria:
- Female sex
- Age: 18 - 35 years
- Nulliparous
- Body mass index (BMI): 18.5 - 24.9 kg/m2
- Premenopausal, with regular menstrual cycle (every 21-38 days, by self-report)
- Sedentary or recreationally active, defined as: <300 minutes per week of voluntary exercise at moderate intensity or greater over the past 12 weeks
- Not currently pregnant or lactating, not planning to become pregnant in the next 12 weeks
- Ability and willingness to fast for 12 hours before each study day visit
If applicable:
- For people who occasionally (i.e., <1x/day) use cannabis (including cannabidiol-based products): ability and willingness to abstain from cannabis for two days prior to each study day visit, the day of each study visit, and during each ad libitum diet phase.
- For people who use cannabis daily: ability and willingness to continue to use the exact same amount of cannabis as they normally use for two days prior to each study day visit, the day of each study visit, and during each ad libitum diet phase.
Exclusion Criteria:
Current or previous major comorbidities, by self-report, including:
- Cardiovascular diseases
- Diabetes (type 1 or type 2)
- Cancer
- Thyroid diseases
- Human immunodeficiency virus or hepatitis B or C
- Renal diseases
- Hepatic diseases
- Polycystic ovary syndrome
Uncontrolled/untreated (self-report):
- Hypertension (or measured diastolic blood pressure > 100 mm HG or systolic blood pressure > 160 mm HG)
- Dyslipidemia
- Sleep disorders
- Any other condition that may affect appetite and energy balance
Currently or in the past six months:
- Use of oral contraceptive pills, or any other hormone-related birth control
- Progestin-releasing intrauterine device
- Use of any hormone therapy/medication ( except medication for thyroid conditions, that has not been altered for >6 months)
- Use of regular medication that may affect appetite, energy balance, or sleep
- Regular use of tobacco or nicotine products
- Starting any new prescription medication within two weeks of the first study day visit or during the study
- If applicable, inability to abstain from supplements or herbal products that may impact sex hormones (e.g., chastetree, phytoestrogens, calcium d glucarate, soy isoflavones, maca, black cohosh, red raspberry, etc.) for two weeks prior to the first study day visit and until the second study day visit and free-living assessments are completed.
- Working night shifts or traveling across more than 2 time zones within two weeks of and throughout the study
- Food intolerances or allergies that cannot be accommodated
- History of surgical procedure for weight loss at any time (e.g. gastroplasty, gastric bypass, gastrectomy or partial gastrectomy, adjustable banding, gastric sleeve); history of extensive bowel resection for other reasons
- Current alcohol or substance abuse (score >1 on the cut down-annoyed-guilty-eye opener [CAGE] questionnaire)
- Current or past history of eating disorders including anorexia nervosa, bulimia, binge eating disorder (self-report or score >20 on the Eating Attitudes Test - 26 [EATS-26] questionnaire)
- Current severe depression or history of severe depression within the previous year, based on score > 30 on Beck Depression Inventory (BDI)
- Weight loss >5kg in past 12 weeks for any reason
- Weight loss of >20 kgs in past 3 years for any reason
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Energy intake
Time Frame: 1 hour
|
Ad libitum intake at lunch; difference between energy in weighed food before and after consumption in a laboratory setting
|
1 hour
|
|
Hunger area under the curve
Time Frame: 3 hours (pre and 30, 60, 90, 120, 150, and 180 minutes after breakfast)
|
Repeated visual analog scale (0-100mm) ratings of hunger after a standard breakfast meal
|
3 hours (pre and 30, 60, 90, 120, 150, and 180 minutes after breakfast)
|
|
Satiety area under the curve
Time Frame: 3 hours (pre and 30, 60, 90, 120, 150, and 180 minutes after breakfast)
|
Repeated visual analog scale (0-100mm) ratings of satiety after a standard breakfast meal
|
3 hours (pre and 30, 60, 90, 120, 150, and 180 minutes after breakfast)
|
|
Prospective food consumption area under the curve
Time Frame: 3 hours (pre and 30, 60, 90, 120, 150, and 180 minutes after breakfast)
|
Repeated visual analog scale (0-100mm) ratings of prospective food consumption after a standard breakfast meal
|
3 hours (pre and 30, 60, 90, 120, 150, and 180 minutes after breakfast)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Free-living ad libitum energy intake
Time Frame: 2.5 days following study visit
|
Ad libitum intake; difference between energy in weighed food before and after consumption, provided to participants in free-living environments
|
2.5 days following study visit
|
|
Resting metabolic rate
Time Frame: 30 minutes
|
Resting metabolic rate, via indirect calorimetry (metabolic cart)
|
30 minutes
|
|
Body composition
Time Frame: 30 minutes
|
Fat mass and fat-free mass from dual X-ray absorptiometry
|
30 minutes
|
|
Estradiol
Time Frame: 5 minutes
|
Concentration of circulating estradiol, measured from saliva
|
5 minutes
|
|
Progesterone
Time Frame: 5 minutes
|
Concentration of circulating progesterone, measured from saliva
|
5 minutes
|
|
Physical activity patterns
Time Frame: 7 days
|
Physical activity patterns (e.g., steps/day, time spent sitting, or in moderate-to-vigorous physical activity) from activPAL accelerometers
|
7 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 1, 2022
Primary Completion (Actual)
October 30, 2024
Study Completion (Actual)
October 30, 2024
Study Registration Dates
First Submitted
February 27, 2024
First Submitted That Met QC Criteria
March 21, 2024
First Posted (Actual)
March 25, 2024
Study Record Updates
Last Update Posted (Actual)
May 1, 2026
Last Update Submitted That Met QC Criteria
April 27, 2026
Last Verified
April 1, 2026
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 22-00874
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
De-identified data will be made available to researchers upon reasonable request.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
University of Vermont Medical CenterAvocado Nutrition CenterRecruitingHealthy | Healthy Volunteers | Healthy Subjects | Healthy Volunteer | Healthy Adult | Healthy Volunteers Only | Healthy Male and Female Subjects | Healthy Non-smokersUnited States
-
Dragonfly TherapeuticsRecruitingHealthy | Healthy Participants | Healthy Adult Females | Volunteer | Healthy Adult MaleAustralia
-
University of PalermoCompletedHealthy | Healthy Volunteers | Healthy Subjects | Healthy Participants | Static Stretching | Stretch | StretchingItaly
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Umm Al-Qura UniversityActive, not recruitingHealthy | Healthy Participants | Healthy Adult | Healthy Women | Healthy Adult Females | Healthy Adult Participants | Healthy Young Adults | Healthy Adult Female Participants | Healthy Adult Male | Poor Sleep Quality | Healthy (Controls) | Poor Sleeping Quality | Healthy Adult Male Subjects | Health Adult SubjectsSaudi Arabia
-
University of PalermoCompletedHealthy Participants | Healthy Adult Participants | Healthy Young AdultsItaly
-
PfizerNot yet recruitingHealthy | Healthy AdultsUnited States
-
Atisama TherapeuticsRecruitingHealthy | Healthy SmokerAustralia
Clinical Trials on No intervention
-
Hopital FochNot yet recruitingInterstitial Lung DiseaseFrance
-
Wave NeuroscienceCompletedAutistic DisorderUnited States
-
University of Alabama at BirminghamCompletedInflammatory Bowel Diseases | Colorectal Cancer | Diverticular Diseases | Social BehaviorUnited States
-
Janssen Research & Development, LLCCompletedLupus Erythematosus, Systemic | Lupus Erythematosus, Cutaneous | Lupus Erythematosus, DiscoidUnited States, Poland
-
Hospital Universitario La Paz3MVX CCB and Agaplesion Markus Krankenhaus, Frankfurt a.M., Germany.; Department...RecruitingEmbolism | Atrial Fibrillation | Arrhythmia | Stroke, Acute | Stroke Sequelae | AblationSpain
-
Southern California College of Optometry at Marshall...Ohio State University; University of Houston; Alcon Research; University of Waterloo and other collaboratorsCompletedContact Lens Complication | Contact Lens Acute Red Eye | Contact Lens Related Corneal Infiltrate (Disorder) | Contact Lens-Induced Corneal Fluorescein StainingUnited States, Canada
-
Huashan HospitalZhejiang Cancer Hospital; Shanghai Zhongshan Hospital; Tongji Hospital; Qilu Hospital... and other collaboratorsRecruitingHead and Neck Squamous Cell Carcinoma | Patient Derived Organoid | Drug Sensitive Test in VitroChina
-
China Medical University HospitalUnknownIntention to Stay, Turnover Behavior
-
University of Dublin, Trinity CollegeCompleted